Press Release

Quetzal Therapeutics Debuts with Expert Leadership, High-Impact Pipeline and $50 Million of Committed Capital

Quetzal Therapeutics, a newly formed biopharmaceutical company, announced its official launch today with $50 million of committed capital.

Share this article:
Facebook
Twitter
LinkedIn
Email
Print

Have questions or want to connect?

We’re here to help—reach out to learn more about Quetzal Therapeutics and our mission.
Contact Us